D.E. Shaw & Co’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

D.E. Shaw & Co’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-47,214	Closed	-$6.21M	–	4685
2020 Q4	$6.21M	Buy	+47,214	New	+$4.17M	0.01%	1705
2020 Q1	–	Sell	-4,837	Closed	-$278K	–	4413
2019 Q4	$278K	Sell	4,837 -11,418	-70%	-$565K	﹤0.01%	3664
2019 Q3	$585K	Buy	+16,255	New	+$635K	﹤0.01%	3136

D.E. Shaw & Co's EIDX Position: Q1 2021 in Review

D.E. Shaw & Co sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 47,214 shares — an estimated $6.21M sold.

D.E. Shaw & Co first reported a position in EIDX in Q3 2019 and held it in 3 quarters. The position peaked at $6.21M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

D.E. Shaw & Co reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
D.E. Shaw & Co sold 47,214 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $6.21M.
D.E. Shaw & Co first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2019 and held it in 3 quarters.
D.E. Shaw & Co's Eidos Therapeutics, Inc. Common Stock position peaked at $6.21M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.